Serina Therapeutics, Inc.
NYSE · Healthcare · Pharmaceutical Preparations · Huntsville, AL
SER chart
What traders are saying about $SER
Latest postsSerina Therapeutics, Inc. news
- Serina Therapeutics (SER) Edges 1.08% Lower to $1.83 as Shares Drift Toward Lower End of Range - Donchian Channel
https://www.siam.in/ ·
- A passive investor reports 2 million Serina Therapeutics (SER) shares in an amended disclosure.
Stock Titan ·
- Epigenetic Reprogramming Longevity Therapeutics Global Market Report 2026 | Capture $16.14B AI and Cell Reprogramming Growth as Retro Biosciences, Altos Labs and NewLimit Lead
Yahoo Finance ·
- Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event "A New Approach to Advanced Parkinson’s Disease: Serina Discusses SER-252’s Clinical Progress"
Yahoo Finance ·
- Serina Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Yahoo Finance ·
- Serina Therapeutics Reports Cohort 1 Observations from SER-252 Registrational Study in Advanced Parkinson’s Disease and Advances to Cohort 2
Yahoo Finance ·
- Serina Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
Yahoo Finance ·
- Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
Yahoo Finance ·
- Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Yahoo Finance ·
- Serina Therapeutics Appoints Farrell Simon to its Board of Directors
Yahoo Finance ·
- Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson’s Disease
Yahoo Finance ·
- Gannet BioChem and Serina Therapeutics Enter Development Partnership Supporting SER-252 Program
Yahoo Finance ·
Serina Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $130,000 | $56,000 | $3.2M | $34,000 |
| Net income | -$19.2M | -$11.1M | $5.3M | -$10.5M |
| Diluted EPS | $-1.91 | $-1.51 | $0.73 | $-9.70 |
| Total assets (year end) | $7.0M | $6.7M | $9.0M | $3.2M |
| Cash and equivalents (year end) | $3.1M | $3.7M | $7.6M | $645,000 |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Serina Therapeutics, Inc.
- Ticker
- SER (NYSE)
- Industry
- Pharmaceutical Preparations
- Headquarters
- Huntsville, AL
- Incorporated in
- AL
- Fiscal year end
- December 31
- SEC CIK
- 1708599
- Former names
- AgeX Therapeutics, Inc.
Frequently asked questions
What exchange is Serina Therapeutics, Inc. listed on?
Serina Therapeutics, Inc. trades on the NYSE under the ticker symbol SER.
What industry is Serina Therapeutics, Inc. in?
Serina Therapeutics, Inc. is classified by the SEC under "Pharmaceutical Preparations", part of the Healthcare sector on StockTweeting.
Where is Serina Therapeutics, Inc. headquartered?
Serina Therapeutics, Inc.'s business address on file with the SEC is in Huntsville, AL.
When does Serina Therapeutics, Inc.'s fiscal year end?
Serina Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Serina Therapeutics, Inc. report?
Serina Therapeutics, Inc. reported $130,000 in revenue for calendar year 2025, according to its SEC filings.